Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sialic acid binding Ig-like lectin 18, pseudogene (SIGLEC18P) is a human pseudogene belonging to the Siglec (sialic acid-binding immunoglobulin-like lectin) family. Unlike other Siglec genes that encode glycan-recognizing immune modulatory proteins, SIGLEC18P does not produce a functional protein product due to disabling mutations in its coding sequence. Siglec pseudogenes, including SIGLEC18P, are remnants of once-functional immune regulators that have lost protein-coding capacity in humans, although homologous genes in other primates may still be active. SIGLEC18P is not considered a valid target for therapeutic intervention or pharmacological modulation.
Not applicable (no protein product)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sialic acid binding Ig-like lectin 18, pseudogene (SIGLEC18P).